INTRODUCTION: Covid-19 is associated with a high risk of venous thromboembolism. In addition, cases of arterial thromboembolism were also reported. We investigated the effect of antiplatelet therapy on the disease course. METHODS: We evaluated a cohort of inpatients with Covid-19 (n ​= ​152). We recorded the patient's demographic data, their comorbidities, medication use including the use of antiplatelets and anticoagulants, laboratory findings and data about mechanical ventilation. We then separated the patient's outcomes into either being "bad" (dead or referral to higher level of care) or "good" (discharged). Then we evaluated the factors that contributed to the patient needing ventilatory support and to showing typical radiological findings. RESULTS: In our cohort, 21 patients received ventilatory support whereas 131 did not require the use of ventilators. 127 patients had good outcomes and 25 had bad outcomes. By using multivariate analysis, we found that the need for ventilatory support was the strongest predictor of a bad outcome. All patients who were on ventilators displayed typical radiological findings. The factors predicting the need for ventilatory support were LDH and CRP levels, the presence of cardiac conduction abnormalities as well as chronic lung conditions. Cardiac conduction abnormalities, LDH and CRP levels, and the use of antiplatelets, were factors that predicted typical radiological findings. CONCLUSIONS: There was a higher incidence of typical radiological findings in patients on antiplatelet medication. However, it did not translate into changes in the ventilation requirement or in the outcome. The need for mechanical ventilation was the strongest predictor of a bad outcome.

Geriatric Center Pardubice Hospital Kyjevska 44 532 03 Pardubice Czech Republic

Klinikum Fichtelgebirge Haus Selb Medizinische Klinik Weißenbacher Str 62 95100 Selb Germany

Zobrazit více v PubMed

Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D.A.M.P.J., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., V Huisman M., Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013. PubMed DOI PMC

Edler C., Schröder A.S., Aepfelbacher M., Fitzek A., Heinemann A., Heinrich F., Klein A., Langenwalder F., Lütgehetmann M., Meißner K., Püschel K., Schädler J., Steurer S., Mushumba H., Sperhake J.-P. Dying with SARS-CoV-2 infection—an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int. J. Leg. Med. 2020;134:1275–1284. doi: 10.1007/s00414-020-02317-w. PubMed DOI PMC

Maldonado E., Tao D., Mackey K. Antithrombotic therapies in COVID-19 disease: a systematic review. J. Gen. Intern. Med. 2020:1–9. doi: 10.1007/s11606-020-05906-y. PubMed DOI PMC

Chen G., Wu D., Guo W., Cao Y., Huang D., Wang H., Wang T., Zhang X., Chen H., Yu H., Zhang X., Zhang M., Wu S., Song J., Chen T., Han M., Li S., Luo X., Zhao J., Ning Q. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020;130:2620–2629. doi: 10.1172/JCI137244. PubMed DOI PMC

Mohamed-Hussein A.A.R., Aly K.M.E., Ibrahim M.-E.A.A. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Med. Hypotheses. 2020;144 doi: 10.1016/j.mehy.2020.109975. PubMed DOI PMC

Song W.-C., FitzGerald G.A. COVID-19, microangiopathy, hemostatic activation, and complement. J. Clin. Invest. 2020 doi: 10.1172/JCI140183. PubMed DOI PMC

Violi F., Pastori D., Cangemi R., Pignatelli P., Loffredo L. Hypercoagulation and antithrombotic treatment in coronavirus 2019: a new challenge. Thromb. Haemostasis. 2020 doi: 10.1055/s-0040-1710317. PubMed DOI PMC

Feldt T., Guggemos W., Heim K., Klug B., Lehnert R., Lübbert C., Niebank M., Pfäfflin F., Rothfuss K., Schmiedel S., Stegemann M.S., Stich A., Wolf T. Hinweise zu Erkennung, Diagnostik und Therapie von Patienten mit COVID-19. 2020. DOI

V Diaz J., WHO G. 2020. Clinical Management of COVID-19.http://repositorio.unan.edu.ni/2986/1/5624.pdf

Valderrama E.V., Humbert K., Lord A., Frontera J., Yaghi S. Severe acute respiratory syndrome coronavirus 2 infection and ischemic stroke. Stroke. 2020 doi: 10.1161/STROKEAHA.120.030153. STROKEAHA120030153. PubMed DOI

Lala A., Johnson K.W., Januzzi J.L., Russak A.J., Paranjpe I., Richter F., Zhao S., Somani S., Van Vleck T., Vaid A., Chaudhry F., De Freitas J.K., Fayad Z.A., Pinney S.P., Levin M., Charney A., Bagiella E., Narula J., Glicksberg B.S., Nadkarni G., Mancini D.M., Fuster V. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. J. Am. Coll. Cardiol. 2020 doi: 10.1016/j.jacc.2020.06.007. PubMed DOI PMC

Escalard S., Maïer B., Redjem H., Delvoye F., Hébert S., Smajda S., Ciccio G., Desilles J.-P., Mazighi M., Blanc R., Piotin M. Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from paris. Stroke. 2020 doi: 10.1161/STROKEAHA.120.030574. STROKEAHA120030574. PubMed DOI PMC

Falcone M., Russo A., Cangemi R., Farcomeni A., Calvieri C., Barillà F., Scarpellini M.G., Bertazzoni G., Palange P., Taliani G., Venditti M., Violi F. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J. Am. Heart Assoc. 2015;4 doi: 10.1161/JAHA.114.001595. PubMed DOI PMC

Torrinhas R.S., Calder P.C., Waitzberg D.L. Letter to the Editor in relation to Bistrian BR. Parenteral fish oil emulsions in critically ill COVID-19 emulsions [published online ahead of print, 2020 May 8] JPEN - J. Parenter. Enter. Nutr. 2020;2020 doi: 10.1002/jpen.1871. JPEN. J. Parenter. Enteral Nutr. PubMed DOI PMC

Kwiatkowski S., Borowski D., Kajdy A., Poon L.C., Rokita W., WielgoŚ M. Why we should not stop giving aspirin to pregnant women during the COVID-19 pandemic. Ultrasound Obstet. Gynecol. 2020 doi: 10.1002/uog.22049. PubMed DOI PMC

Bikdeli B., V Madhavan M., Jimenez D., Chuich T., Dreyfus I., Driggin E., Der Nigoghossian C., Ageno W., Madjid M., Guo Y., V Tang L., Hu Y., Giri J., Cushman M., Quéré I., Dimakakos E.P., Gibson C.M., Lippi G., Favaloro E.J., Fareed J., Caprini J.A., Tafur A.J., Burton J.R., Francese D.P., Wang E.Y., Falanga A., McLintock C., Hunt B.J., Spyropoulos A.C., Barnes G.D., Eikelboom J.W., Weinberg I., Schulman S., Carrier M., Piazza G., Beckman J.A., Steg P.G., Stone G.W., Rosenkranz S., Goldhaber S.Z., Parikh S.A., Monreal M., Krumholz H.M., V Konstantinides S., Weitz J.I., Lip G.Y.H. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J. Am. Coll. Cardiol. 2020 doi: 10.1016/j.jacc.2020.04.031. PubMed DOI PMC

Maharaj R. King’s critical care – evidence summary clinical management of COVID-19. 2020. https://scts.org/wp-content/uploads/2020/03/01-Kings-Critical-Care-COVID19-Evidence-Summary-9th-March-2020.pdf

Mezera V., Fekete D., Bureš I. Geriatric scales and rehabilitation after proximal femur fractures. Geriatr. a Gerontol. 2019;8:107–111. https://www.prolekare.cz/casopisy/geriatrie-gerontologie/2019-3-15/geriatricke-skaly-a-rehabilitace-po-zlomeninach-proximalniho-femuru-116936

Paranjpe I., Fuster V., Lala A., Russak A., Glicksberg B.S., Levin M.A., Charney A.W., Narula J., Fayad Z.A., Bagiella E., Zhao S., Nadkarni G.N. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 2020 doi: 10.1016/j.jacc.2020.05.001. PubMed DOI PMC

Ji D., Zhang D., Xu J., Chen Z., Yang T., Zhao P., Chen G., Cheng G., Wang Y., Bi J., Tan L., Lau G., Qin E. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa414. PubMed DOI PMC

Zhang G., Zhang J., Wang B., Zhu X., Wang Q., Qiu S. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis. Respir. Res. 2020;21:74. doi: 10.1186/s12931-020-01338-8. PubMed DOI PMC

Liang W., Liang H., Ou L., Chen B., Chen A., Li C., Li Y., Guan W., Sang L., Lu J., Xu Y., Chen G., Guo H., Guo J., Chen Z., Zhao Y., Li S., Zhang N., Zhong N., He J. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern. Med. 2020 doi: 10.1001/jamainternmed.2020.2033. PubMed DOI PMC

Wu C., Chen X., Cai Y., Xia J., Zhou X., Xu S., Huang H., Zhang L., Zhou X., Du C., Zhang Y., Song J., Wang S., Chao Y., Yang Z., Xu J., Zhou X., Chen D., Xiong W., Xu L., Zhou F., Jiang J., Bai C., Zheng J., Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China. JAMA Intern. Med. 2020 doi: 10.1001/jamainternmed.2020.0994. PubMed DOI PMC

Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., Ma K., Xu D., Yu H., Wang H., Wang T., Guo W., Chen J., Ding C., Zhang X., Huang J., Han M., Li S., Luo X., Zhao J., Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi: 10.1136/bmj.m1091. PubMed DOI PMC

Li X., Xu S., Yu M., Wang K., Tao Y., Zhou Y., Shi J., Zhou M., Wu B., Yang Z., Zhang C., Yue J., Zhang Z., Renz H., Liu X., Xie J., Xie M., Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J. Allergy Clin. Immunol. 2020 doi: 10.1016/j.jaci.2020.04.006. PubMed DOI PMC

Watson R.A., Johnson D.M., Dharia R.N., Merli G.J., Doherty J.U. Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp. Pract. 1995;2020 doi: 10.1080/21548331.2020.1772639. PubMed DOI PMC

Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemostasis. 2020;18:1094–1099. doi: 10.1111/jth.14817. PubMed DOI PMC

Kluge S., Janssens U., Welte T., Weber-Carstens S., Marx G., Karagiannidis C. Empfehlungen zur intensivmedizinischen Therapie von Patienten mit COVID-19. Atemwegs- Und Lungenkrankheiten. 2020;46:245–248. doi: 10.5414/ATX02525. PubMed DOI PMC

Klok F.A., Kruip M.J.H.A., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., V Huisman M., Endeman H. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb. Res. 2020;191:148–150. doi: 10.1016/j.thromres.2020.04.041. PubMed DOI PMC

Meng J., Xiao G., Zhang J., He X., Ou M., Bi J., Yang R., Di W., Wang Z., Li Z., Gao H., Liu L., Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg. Microb. Infect. 2020;9:757–760. doi: 10.1080/22221751.2020.1746200. PubMed DOI PMC

Fosbøl E.L., Butt J.H., Østergaard L., Andersson C., Selmer C., Kragholm K., Schou M., Phelps M., Gislason G.H., Gerds T.A., Torp-Pedersen C., Køber L. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. J. Am. Med. Assoc. 2020 doi: 10.1001/jama.2020.11301. PubMed DOI PMC

Viecca M., Radovanovic D., Forleo G.B., Santus P. Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study. Pharmacol. Res. 2020;158:104950. doi: 10.1016/j.phrs.2020.104950. PubMed DOI PMC

COVID-19 associated coagulopathy: Mechanisms and host-directed treatment